1. Search Result
Search Result
Results for "

MDS

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

3

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139076

    Epigenetic Reader Domain Metabolic Disease Cancer
    Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .
    Menin-MLL inhibitor 19
  • HY-13634A
    Ezatiostat
    5+ Cited Publications

    TER199(free base); TLK199

    Glutathione S-transferase Apoptosis Cancer
    Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .
    Ezatiostat
  • HY-16018A

    ABT-348 hydrochloride

    Aurora Kinase PDGFR VEGFR Cancer
    Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib hydrochloride
  • HY-16018

    ABT-348

    Aurora Kinase VEGFR PDGFR Cancer
    Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib
  • HY-P99445

    APG101; CAN008

    TNF Receptor Inflammation/Immunology Cancer
    Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
    Asunercept
  • HY-15229
    Guadecitabine sodium
    Maximum Cited Publications
    9 Publications Verification

    SGI-110 sodium; S-110 sodium

    DNA Methyltransferase Cancer
    Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
    Guadecitabine sodium
  • HY-P99555

    OPN-305

    Toll-like Receptor (TLR) Inflammation/Immunology
    Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS) .
    Tomaralimab
  • HY-13634

    TER199; TLK199 hydrochloride

    Glutathione S-transferase Apoptosis Cancer
    Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .
    Ezatiostat hydrochloride
  • HY-13542

    SGI-110

    DNA Methyltransferase Cancer
    Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
    Guadecitabine
  • HY-132189

    P-glycoprotein Cancer
    Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters . Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . Laniquidar has limited oral bioavailability .
    Laniquidar
  • HY-114226
    Olutasidenib
    1 Publications Verification

    FT-2102

    Isocitrate Dehydrogenase (IDH) Inflammation/Immunology Cancer
    Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
    Olutasidenib
  • HY-16398

    DNA Alkylator/Crosslinker Cancer
    Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .
    Pipobroman

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: